KEGG   DRUG: Afasevikumab
Entry
D10902                      Drug                                   
Name
Afasevikumab (USAN/INN)
Sequence
(Heavy chain)
EVQLVESGGG LVQPGRSLRL SCAASGFTFD DYAMHWVRQA PGKGLEWVSG INWSSGGIGY
ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TALYYCARDI GGFGEFYWNF GLWGRGTLVT
VSSASTKGPS VFPLAPSSKS TSGGTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL
QSSGLYSLSS VVTVPSSSLG TQTYICNVNH KPSNTKVDKR VEPKSCDKTH TCPPCPAPEL
LGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS
REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK
SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK
(Light chain)
EIVLTQSPAT LSLSPGERAT LSCRASQSVR SYLAWYQQKP GQAPRLLIYD ASNRATGIPA
RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPPATFG GGTKVEIKRT VAAPSVFIFP
PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
(Disulfide bridge: H22-H96, H150-H206, H226-L215, H232-H'232, H235-H'235, H267-H327, H373-H431, H'22-H'96, H'150-H'206, H'226-L'215, H'267-H'327, H'373-H'431, L23-L88, L135-L195, L'23-L'88, L'135-L'195)
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Efficacy
Anti-inflammatory, Anti-IL-17A/IL-17F antibody
  Type
Monoclonal antibody, bispecific antibody
Target
IL17A [HSA:3605] [KO:K05489]
IL17F [HSA:112744] [KO:K05494]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04657  IL-17 signaling pathway
hsa04659  Th17 cell differentiation
Brite
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D10902  Afasevikumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL17A
     D10902  Afasevikumab (USAN/INN)
    IL17F
     D10902  Afasevikumab (USAN/INN)
Other DBs
CAS: 1589503-30-9
PubChem: 342581763
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system